Section
A 12-year-old female with primary failure of eruption (PFE) affecting the right mandibular first molar is treated successfully via extraction and orthodontic repositioning, restoring function and occlusion.
In vivo awake recordings in transgenic mice show APOE ε4 reduces neuronal excitability in the anterior olfactory nucleus (AON); adult females are more excitable than males (a sex difference lost with aging), while aging amplifies network os
A JCI study links recessive CPD missense variants to congenital deafness, defines a pathogenic mechanism through impaired arginine–NO–cGMP signaling with ER stress and apoptosis, and shows rescue in models with arginine or sildenafil — offe
A single‑arm trial of AAV‑OTOF (Anc80L65) in 10 patients (1.5–23.9 years) with autosomal recessive deafness 9 showed good tolerability and rapid, clinically meaningful hearing gains, with optimal outcomes in children aged 5–8 years; longer
A 2022–2024 nonblinded cohort study found OTOF gene therapy produced rapid, durable gains in auditory thresholds, speech perception, mismatch-negativity responses, and music perception versus cochlear implantation in children with genetical
A randomized crossover trial in older adults found that hearing-loss severity — not cognition or prior hearing-aid experience — predicts preference for slow versus fast compression; speech recognition in quiet and noise was unchanged by com
A prospective cross-sectional study finds unilateral chronic otitis media with effusion (COME) in children is associated with poorer spatial release from masking and high tinnitus prevalence, suggesting potential central auditory consequenc
The NLRP3 inflammasome plays a central role in inflammation-mediated sensorineural hearing loss (SNHL). Genetic and acquired activation causes cochlear damage through cytokine release and pyroptosis. Targeted therapies, including IL-1 block
The WHAM longitudinal study finds modest psychosocial benefits from hearing‑aid uptake—reduced depression in people without tinnitus and lower loneliness in older adults—while showing limited mediation by self-perceived hearing disability a
A multicenter retrospective cohort shows weekly low‑dose cisplatin markedly lowers ototoxicity compared with standard high‑dose every‑3‑week cisplatin in CRT for head and neck squamous cell carcinoma, with similar two‑year survival.
In 185 children receiving unilateral cochlear implants, residual acoustic hearing favored the non-implanted ear in quiet (especially for SSD), but noise attenuated that advantage. Shorter auditory deprivation and longer CI experience reduce
Early cochlear implantation in children with prelingual single-sided deafness improves spatial hearing and cognitive outcomes, supporting neurodevelopment and mitigating risks of auditory deprivation and cortical reorganization.
A retrospective 10‑year series from Perth Children’s Hospital reports heterogeneous long‑term outcomes after pediatric cochlear implantation for single‑sided deafness; earlier implantation (within 1 year) was associated with greater l
In 284,175 US veterans, nonmodifiable pre‑fitting factors—health comorbidity, mental status, prior hearing‑aid experience, age, race/ethnicity, and partnership—were independently associated with 2‑year hearing‑aid use persistence, beyond au
A visual-world eye-tracking study in older adults shows that postlingual hearing loss delays verb-driven semantic prediction—especially under higher listening demand—while simple agent-based prediction is preserved.
A PRISMA systematic review and meta-analysis of 17 studies (2019–2024) found type 2 diabetes is associated with a 4.19-fold greater odds of hearing loss, especially at high frequencies; duration >10 years and higher HbA1c amplified risk.
DB-OTO, a hair-cell-specific dual-AAV gene therapy encoding full-length human otoferlin, achieved dose-dependent and sustained auditory restoration in OTOF-deficient mice, supporting an ongoing Phase I/II pediatric trial.
A Finnish longitudinal study reveals that elevated Epstein-Barr virus antibody levels are significantly associated with persistent oral HPV infections, highlighting potential viral interplay in oropharyngeal oncogenesis risk.
Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting
Regeneron’s DB-OTO gene therapy shows promising results in restoring natural hearing in children with profound hearing loss caused by OTOF gene mutations, with 75% achieving significant hearing improvement after a single treatment.
